ICU sedation, delirium & recovery
Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients
Main findingResult — go to the resultAdjusted risk difference 0.6% 95% CI −1.8% to 3.0%Authors' conclusion
In this comparative effectiveness study of a multicenter cohort of adult patients with thyroid storm, no significant differences were found in mortality or adverse events in patients who were treated with propylthiouracil or methimazole.
Study context
- Population
- Adults admitted to intensive or intermediate care units with a diagnosis of thyroid storm, treated with propylthiouracil or methimazole, US Premier Healthcare Database, 2016–2020
- Participants
- 1,383 adults
- Exposure
- Propylthiouracil vs methimazole
- Propylthiouraciln = 656
- Methimazolen = 727reference
- Outcome
- In-hospital death or discharge to hospice (adjusted risk difference)
Methodological detailsretrospective cohort, multicentre, targeted maximum likelihood estimation
- Retrospective cohort
- Multicentre
- Targeted maximum likelihood estimation
Main finding
As reported in the abstract
Adjusted risk difference
0.6%
95% CI −1.8% to 3.0%
P = 0.64
Events by group
Propylthiouracil vs Methimazole
adjusted risk difference 0.6% (95% CI −1.8% to 3.0%); P = 0.64
Observational data: associations, not effects.
Further findings
Duration of organ support, total hospitalization costs
- No significant differences between the 2 groups
Safety
Adverse events
- No significant difference in rates between the 2 groups
Original publication
Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients. JAMA Netw Open. Published 3 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →